---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-300647"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-11-26T23:59:59+00:00"
generated_at: "2026-05-16T16:34:13.137083+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics appoints James R. Meyers to Board of Directors

## Summary
- James R. Meyers appointed as Class II Director effective Nov 25, 2025; term expires at 2026 annual meeting.
- Appointed to Audit Committee; received nonstatutory stock option for 25,000 shares vesting monthly over 3 years.
- Annual cash retainer of $40k plus $10k Audit Committee retainer, pro-rated for 2025.
- Eligible for annual option grant at 2026 meeting: lesser of 14,000 shares or fair value not exceeding $400,000.

## SEC filing metadata
- accession: 0001193125-25-300647
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-11-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312525300647/0001193125-25-300647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312525300647/vera-20251125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-300647
- JSON: https://secwatch.observer/filing/0001193125-25-300647.json
- Plain text: https://secwatch.observer/filing/0001193125-25-300647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.